Full-Time

Vice President – Supply Chain

Posted on 9/5/2025

BridgeBio

BridgeBio

501-1,000 employees

Develops therapies for genetic diseases

Compensation Overview

$335k - $392.5k/yr

+ Bonus + Equity

San Francisco, CA, USA

Hybrid

Hybrid: in-office 2-3x per week in SF.

Category
Operations & Logistics (1)
Requirements
  • Fifteen years of experience in Supply Chain Management and/or Manufacturing functions in the pharmaceutical and/or biotechnology industries. Title based on experience
  • Bachelor’s or Master’s Degree in a scientific discipline
  • Detailed understanding of the pharmaceutical business, including both clinical development and manufacturing and commercial manufacturing and supply chain
  • Proven experience with forecasting, demand/supply planning, inventory management, packaging, labeling and distribution including cold chain, import/export and reverse logistics
  • Proven experience managing and developing a team of professionals
  • Experience with SAP or similar ERP platform
  • Experience with product serialization, TraceLink or other similar platform and DSCSA standards
  • Experience with Veeva, or other similar QMS platform
  • Experience with clinical blinding practices
  • Experience in assisting set-up of IRT Systems for global clinical studies
  • Demonstrated skills in project management and vendor management
  • Working knowledge of drug development process (Phase I-IV)
  • Working knowledge of current GMP/GCP/GDP guidance and regulations
  • Familiar with US and EU import/export regulations
  • Excellent attention to detail, strong data analysis, problems solving and decision-making ability in fast-paced environment
  • Proven ability to effectively develop, communicate, and gain support for execution plans with a wide range of stakeholders
  • Ability to handle multiple projects simultaneously
  • Other Information: Position may require occasional evening and/or weekend commitment
  • Position may require occasional travel (up to 20%), domestic and international
  • Salary is competitive and commensurate with experience and qualifications
  • You have demonstrated curiosity and adaptability in adopting AI-powered tools and technologies
Responsibilities
  • Manage a global team of supply chain professionals, responsible for both clinical and commercial end-to-end supply chain
  • Manage all aspects of commercial supply chain, including Drug Substance and Drug Product Contract Manufacturing Organizations (CMOs), Packaging and Labeling activities with Contract Packaging organizations (CPOs), Finished Good receiving, put away, storage and distribution activities at Third Part Logistics Providers (3PLs)
  • Coordinate logistics of material transfer for clinical and commercial drug substance, drug product and components to/from international CMOs/CPOs, managing exportation, applicable USDA/FDA licenses and permits, VAT recovery and customs brokers
  • Own the global Sales & Operations Planning (S&OP) process for all commercial products, coordinating with global market access team for demand planning, finance team for financial planning and driving ownership of final supply plan to be communicated to global partners
  • Own and actively manage the commercial supply plan, all commercial inventory, both in process and finished goods; manage shelf life and expiration
  • Own and manage all serialization activities for commercial products globally
  • Manage clinical packaging and labeling activities including label design, translation, production, distribution and inventory management
  • Provide clinical demand signals, translate the total demand into a demand forecast over time based on a clinical protocol or study overview
  • Prepare a clinical supply plan to support the demand, including determination of supply overage amounts, monitor inventory and provide regular inventory update to project teams
  • Monitor clinical drug expiry/retest dating; initiate inventory release and re-supply, serving as the unblinded inventory manager
  • Manage domestic and international distribution and logistics for clinical programs, including importing and exporting clinical supplies and developing distribution instructions with clinical supply vendors
  • Support budget activities, including managing supplier contracts, PO generation and invoicing approvals for clinical and commercial purchases
  • Work collaboratively with QA to manage supply chain activities such as batch release, final release, temperature excursions and to support the investigation of any deviations in a timely manner
  • Work with CMC as a liaison to clinical operations and also on the evaluation of new CMOs or CPOs for commercial supply chain
  • Work with Global Trade & Distribution and global Finance teams to manage global 3PLs, ensuring quality Finished Good inventory management, distribution and logistics, sales and revenue reporting
  • Generate and maintain global SOPs in Veeva QMS and ensure updates and compliance with industry standards
  • Develop and maintain strong internal cross-functional collaboration with stakeholders, such as CMC, Clinical Operations, Market Access, Finance, Quality, and Regulatory Affairs
Desired Qualifications
  • APICS certification or supply chain education preferred
  • You have demonstrated curiosity and adaptability in adopting AI-powered tools and technologies

BridgeBio Pharma develops medicines for genetic diseases through a decentralized subsidiary model, with each subsidiary focused on a specific disease while sharing central resources. It advances multiple drug programs at once by using genome sequencing, molecular biology, and patient data to identify targets and translate research into therapies. Therapies target the underlying genetic causes to create disease-modifying treatments, and BridgeBio monetizes via licensing, partnerships, and eventual commercialization of approved drugs. The company differentiates itself by its independent subsidiaries with centralized support, data-driven decision making, and a culture of radical transparency, all to accelerate discovery and bring therapies to patients faster.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Palo Alto, California

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Attruby sales hit $146M in Q4 2025 with 44.7% mortality reduction.
  • BBP-418 meets Phase 3 endpoints in LGMD2I/R9 FORTIFY trial May 2026.
  • Farallon Capital boosts stake to 9M shares signaling pipeline confidence.

What critics are saying

  • Pfizer's Vyndamax erodes Attruby share via payer preference within 12 months.
  • $1.2B debt triggers breaches if Attruby growth drops below 30% YoY.
  • FDA rejects BBP-812 Canavan program halting 40% early pipeline value.

What makes BridgeBio unique

  • Hub-and-spoke model advances 48 disease programs via autonomous subsidiaries.
  • Focuses exclusively on genetic diseases and RAS/PI3Kα-driven cancers.
  • Partners with academics to rescue shelved early-stage genetic research.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Performance Bonus

Company Equity

Unlimited Paid Time Off

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Mar 15th, 2026
BridgeBio Pharma shares drop 8% in a month despite 110% yearly gain and analyst target of $100

BridgeBio Pharma has fallen 8% over the past month and 7% over three months, despite posting a 110.52% one-year total shareholder return and approximately 4x returns over three years. The company closed at $69.41, with analysts from Vestra pointing to a fair value of $100.05, suggesting it's 30.6% undervalued. The valuation gap depends on BridgeBio's late-stage pipeline and its transition from research and development to commercial operations. However, the company continues to carry annual net losses of approximately $724.9 million, keeping financing and execution risks prominent. A separate DCF model estimates future cash flow value at $302.08, though this relies heavily on long-term assumptions around successful regulatory approvals and commercial uptake across its rare disease portfolio.

Yahoo Finance
Mar 7th, 2026
BridgeBio's BBP-418 hits Phase 3 endpoints in LGMD2I/R9, but $673M loss tests diversification thesis

BridgeBio Pharma announced positive interim Phase 3 FORTIFY trial data for BBP-418 in limb-girdle muscular dystrophy type 2I/R9, meeting efficacy endpoints. The company will present expanded results at the 2026 MDA Clinical and Scientific Conference alongside additional research. The successful readout represents a significant step for BBP-418 as a potential therapy for the rare genetic muscle disorder and could help diversify BridgeBio's revenue beyond its single approved drug, Attruby. However, the company remains unprofitable, reporting US$502 million in revenue against a US$725 million net loss in 2025. Analysts project BridgeBio could reach US$1.7 billion in revenue by 2028, with a fair value estimate of US$100.05 per share. The key risk remains high cash burn and potential dilution if expenses continue outpacing revenue growth.

Yahoo Finance
Mar 6th, 2026
Truist raises BridgeBio price target to $95 as Attruby sales hit $146M in Q4

BridgeBio Pharma has received upgraded price targets from analysts following strong fourth-quarter results. Truist raised its target to $95 from $86, maintaining a Buy rating, whilst Morgan Stanley increased its target to $98 from $96 with an Overweight rating. The company reported fourth-quarter revenue of $154.18 million, exceeding the $149.07 million consensus estimate. Pre-announced sales of its drug Attruby reached $146 million, a 35% increase from the third quarter, driven by accelerating new patient additions. CEO Neil Kumar highlighted the company's delivery of three successful Phase 3 trial readouts within three months. BridgeBio develops medicines for patients with genetic diseases and anticipates having six approved products as it completes its first decade.

Yahoo Finance
Jan 20th, 2026
Analysts raise BridgeBio price target to $86 after $362M Attruby revenue in 2025

BridgeBio Pharma has received positive analyst coverage following strong 2025 results. Truist raised its price target to $86 from $80 whilst maintaining a Buy rating, noting unchanged fundamental views from 2025. At the J.P. Morgan Healthcare Conference on 12 January, BridgeBio announced preliminary unaudited revenues of $146 million for the fourth quarter of 2025, bringing full-year product revenue to $362.4 million. The company reported over 6,000 unique prescriptions for Attruby, demonstrating rapid market adoption as a first-choice treatment for newly diagnosed ATTR-CM patients. BridgeBio develops therapies for genetic diseases and cancers, including its oncology-focused spin-off, BridgeBio Oncology Therapeutics, which advances precision cancer treatments targeting oncogenes like RAS and PI3K.

Stock Titan
Jan 16th, 2026
BridgeBio prices $550M convertible notes offering to prefund 2027 debt repayment

BridgeBio has priced an offering of $550 million in convertible senior notes due 2033. The biotech company plans to use the proceeds to prefund the repayment of its existing convertible senior notes due 2027. The refinancing move allows BridgeBio to extend its debt maturity profile by six years whilst managing its capital structure ahead of the 2027 notes coming due.

INACTIVE